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Abstract Proteinase 3 (PR3), a serine proteinase which can
degrade lung tissue, is present in the cystic fibrosis (CF) sputum.
In the present study, PR3 protein and mRNA expression was
determined in circulating neutrophils and monocytes. CF
neutrophils contained similar PR3 concentrations as healthy
controls and poorly expressed PR3 mRNA. In contrast, CF
monocytes showed significantly higher PR3 concentrations than
controls, together with an upregulation of PR3 mRNA expres-
sion especially during pulmonary exacerbation. Interestingly,
antibiotic treatment fully abrogated PR3 mRNA expression and
decreased PR3 protein in monocytes. Our findings highlight a
potential role of monocyte-derived PR3 in CF-associated airway
inflammation.
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1. Introduction
The hallmark of the pathophysiology of cystic ¢brosis (CF)
is the neutrophil-dominated in£ammation which occurs early
in the course of the disease and which is potentiated by
chronic colonization with bacteria and especially Pseudomonas
aeruginosa during pulmonary exacerbation. Indeed, the prog-
nosis in CF is largely dependent upon the airway in£amma-
tion and the incidence, severity and duration of pulmonary
infections in the CF lung disease. For most of the patients,
this disease is lethal between the age of 20^30 due to respira-
tory insu⁄ciency [1].
At the site of infection, when activated neutrophils accumu-
late and die, they release large amounts of various serine
proteinases, myeloperoxidase (MPO) and metalloproteinases
which have a potential to produce tissue injury [2,3]. Because
of its potent matrix degradation capacity, neutrophil elastase
(NE) has been particularly investigated in the respiratory tract
of CF patients. Indeed, NE is involved in epithelial damage of
the lung at very early stages of CF and its pathophysiological
action is aggravated by an insu⁄cient protection by two anti-
proteinases, the K1-anti-trypsin and the secretory leucopro-
tease inhibitor (SLPI) [4]. Proteinase 3 (PR3) [5,6], also called
myeloblastin [7,8], is a serine proteinase homolog to NE and
cathepsin G [5]. PR3 can degrade a variety of extracellular
matrix proteins including elastin, ¢bronectin, type IV collagen
and laminin [9]. Both NE and PR3 can process interleukin-8
[10], a major neutrophil chemoattractant in the lung, which
can stimulate the respiratory burst and release of lysosomal
enzymes. PR3 has also been shown to process tumor necrosis
factor-K [11]. Those properties could explain that tracheal
instillation of PR3 induces emphysema to the hamster [6].
In contrast to NE, PR3 is not inhibited by the SLPI and
can enzymatically process it [12]. We have recently shown
that PR3 is present at signi¢cantly higher levels than NE in
sputum of patients with CF, though circulating neutrophils
contained ¢ve times less PR3 than NE [13]. This di¡erence
was even more pronounced in CF patients during pulmonary
exacerbation with P. aeruginosa. Moreover, PR3 enzymatic
activity which was resistant to SLPI was highly correlated
with the clinical status and the respiratory scores of CF pa-
tients [13].
In the present study, we investigated the cellular origin of
PR3 in patients with CF. We therefore analyzed PR3 intra-
cellular levels and the respective capacity of circulating neu-
trophils and monocytes to upregulate PR3 mRNA expression
in CF patients in relation to pulmonary exacerbation and the
infection state.
2. Materials and methods
2.1. Patients
30 Patients with CF (19 males and 11 females), 12.2 þ 5.5 years of
age (range 0.4^20.3 years), were evaluated. Seven patients had nega-
tive sputum cultures and 23 patients had chronic airway infection with
one or several of the following pathogens: P. aeruginosa (n = 13),
Pseudomonas cepacia (n = 2), Pseudomonas maltophilia (n = 3), Staph-
ylococcus aureus (n = 9) and Haemophilus in£uenzae (n = 8). 16 Patients
presented pulmonary exacerbation de¢ned by the presence of ¢ve or
more of the following parameters: increased cough and sputum pro-
duction, increased respiratory rate or dyspnea, new lung in¢ltrates,
fatigue and decreased exercise tolerance, deterioration of pulmonary
function tests, decreased appetite associated with loss of weight and/or
fever [14]. 14 Patients without pulmonary exacerbation were de¢ned
as being in stable condition of the disease. 10 Patients were investi-
gated before and after 2 weeks of antibiotic treatment. The control
group consisted of 13 healthy donors of the Necker Hospital blood
donation center. The protocol was approved by the Ethics Committee
of the Paris Saint-Antoine University and informed consent was ob-
tained from parents before the study.
2.2. Preparation of monocytes and neutrophils
Peripheral blood (8 ml) was collected on EDTA and processed for
monocytes puri¢cation using a Nycoprep gradient [15]. Neutrophils
were isolated using density centrifugation on Ficoll-Hypaque (Phar-
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macia LKB Biotechnology, Piscataway, NJ, USA). Cytocentrifuged
preparations were obtained and stained with May Grunwald Giemsa.
No morphological modi¢cation was detected in monocytes prepared
from patients before and after antibiotic therapy.
2.3. Measurement of PR3 by enzyme-linked immunosorbent assay
(ELISA)
PR3 ELISA was performed using the anti-PR3 monoclonal anti-
body, WGM2 (kind gift of Dr Csernok, Borstel, Germany) and the
biotinylated PR3 monoclonal antibody (Clone CLB 12.8) as previ-
ously described [13].
2.4. Immunoblotting
Total monocyte lysates from 104 cells were electrophoresed through
a 12.5% sodium dodecyl sulfate-polyacrylamide gel. Immunoblotting
was performed using polyclonal anti-peptide PR3 antibodies [7], re-
vealed by a goat anti-rabbit horseradish peroxidase-conjugated secon-
dary antibody and enhanced chemiluminescence (Amersham Pharma-
cia Biotech, Buckinghamshire, UK).
2.5. Semi-quantitative reverse transcription-polymerase chain reaction
(RT-PCR) analysis
Total RNA was extracted from both monocytes and neutrophils
using a RNeasy Kit (Qiagen GmbH, Hilden, Germany). After dena-
turation at 70‡C, RT was performed at 42‡C for 55 min using Mo-
loney Murine Leukemia Virus Reverse Transcriptase (Superscript II,
Gibco BRL, Life Technologies, Paisley, UK). Expression of PR3,
MPO and control L-actin mRNA in monocytes and neutrophils was
analyzed by semi-quantitative PCR using a GeneAmp PCR System
9600 (Perkin Elmer, Forster City, CA, USA) with the following pri-
mers corresponding to distinct exon sequences: L-actin, sense: 5P-
CGGCATCGTCACCAACTG-3P and antisense: 5P-TGTCACGCAC-
GATTTCCC-3P ; PR3, sense: 5P-CACTGCCTGCGGGACATA-3P
and antisense: 5P-GTCAGGGAAAAGGCGGGT-3P ; MPO, sense:
5P-GACCCCCGCATCAAGAAC-3P and antisense: 5P-CTCTCCCC-
ATCCCACCTA-3P. After denaturation, PCR cycles were conducted
as follows. (i) For L-actin: denaturation 30 s at 94‡C, annealing 20 s
at 62‡C and extension 25 s at 72‡C. (ii) PR3 and MPO: denaturation
30 s at 94‡C, annealing 25 s at 60‡C and extension 30 s at 72‡C. The
number of PCR cycles was determined for PR3 or MPO (45 cycles)
and L-actin (25 cycles) to insure that quanti¢cation of the PCR prod-
ucts was conducted in a linear range of ampli¢cation. The L-actin
PCR reaction was performed using the cDNA preparation from
each patient in order to determine those dilutions providing equal
amounts of RT products for all samples and analyzed using a Phos-
phorImager (Storm, Molecular Dynamics, Sunnyvale, CA, USA). As
a negative control, a parallel PCR was conducted without addition of
cDNA. As a positive control, the PCR reaction was conducted with
cDNA samples obtained from U937 cells. Aliquots of each PCR
reaction were electrophoresed, transferred onto nylon ¢lters and hy-
bridized with the following P32-labelled probes: L-actin, 5P-ACC-
CCGTGCTGCTGACCGAGG-3P ; MPO, 5P-CTTTGACAACCTGC-
ACGATGACCCCTGTCT-3P and PR3, full length cDNA [8].
3. Results
3.1. Neutrophil and monocyte PR3 intracellular contents in
CF patients as compared to controls
PR3 concentrations were compared in neutrophil and
monocyte lysates (adjusted to 107 cells/ml) of CF patients
(n = 10) and healthy controls (n = 13) (Fig. 1A). PR3 concen-
trations in neutrophil lysates did not di¡er between CF pa-
tients and controls (2659 þ 179 versus 2418 þ 148 Wg/ml;
mean þ S.E.M.). Likewise, no di¡erence could be detected be-
tween CF patients without (n = 5) or with (n = 5) pulmonary
exacerbation (2880 þ 629 versus 2523 þ 476 Wg/ml).
PR3 concentrations were much higher in neutrophils than
in monocytes and both in healthy controls (2418 þ 148 versus
96.2 þ 13 Wg/ml, P6 0.0001) and in CF patients (2659 þ 179
versus 271 þ 22 Wg/ml, P6 0.0001) (Fig. 1). However, in con-
trast to neutrophils (Fig. 1A), monocytes of CF patients in a
stable condition showed signi¢cantly higher concentrations of
PR3 than controls (271 þ 22 versus 96 þ 13 Wg/ml, P6 0.01)
(Fig. 1B). Interestingly, the PR3 intracellular content was fur-
ther enhanced in monocytes from CF patients with pulmonary
exacerbation as compared to CF patients with stable condi-
tions (385 þ 68 versus 195 þ 30 Wg/ml, P6 0.05) (Fig. 1B).
3.2. In£uence of the stage of the lung disease on PR3 mRNA
expression in neutrophils and monocytes in CF patients
20 Patients were investigated for PR3 mRNA expression in
CF neutrophils puri¢ed as exempli¢ed in Fig. 2A. PR3
mRNA expression was either undetectable or poorly ex-
pressed in neutrophils, independently of the stage of their
disease (stable condition, n = 8 and pulmonary exacerbation,
n = 12) without any in£uence of antibiotic treatment as exem-
pli¢ed for three patients in Fig. 2B.
Monocytes of CF patients in stable condition (n = 8), puri-
¢ed as exempli¢ed in Fig. 3A, did not show signi¢cant PR3
mRNA expression measured by semi-quantitative RT-PCR
(data not shown). In contrast, PR3 mRNA was heavily ex-
pressed in monocytes of all the patients with pulmonary ex-
acerbation (n = 12) as exempli¢ed in four patients (Fig. 3B,
lanes 1, 3, 5 and 7). Interestingly, PR3 mRNA was no longer
detectable in nine out of 10 patients tested at the time of
Fig. 1. Measurement of neutrophil- and monocyte-derived PR3 in
CF patients as compared to controls. The PR3 concentration was
measured in neutrophils (A) and in monocytes (B). Cells (10U106
cells/ml) were lysed in PBS containing 1% Triton and PR3 was
measured by ELISA in 13 healthy controls and in 10 CF patients
being either in stable condition (n = 5) or having pulmonary exacer-
bation (n = 5). Statistical analysis to compare PR3 concentrations in
di¡erent conditions was performed using the non-parametric Mann-
Whitney test.
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complete remission after a 2 week antibiotic treatment as
exempli¢ed in Fig. 3B, lanes 4, 6 and 8 versus 3, 5 and 7.
In one case, in which no signi¢cant change in leukocyte count
and no improvement of pulmonary function was found, PR3
mRNA was still expressed after antibiotic treatment (Fig. 3B,
lane 2 versus 1). These results demonstrate that mPR3 expres-
sion in monocytes is highly correlated with the in£ammation/
infection state. At the protein level, at the time of pulmonary
exacerbation, PR3 protein could also be detected by immuno-
blot analysis of monocyte lysates in the four patients explored
and signi¢cantly decreased following successful antibiotic
therapy (Fig. 3C, lanes 4, 6 and 8 versus 3, 5 and 7), except
for the patient who did not respond to antibiotic treatment
(Fig. 3C, lane 2 versus 1). We then investigated whether the
expression of MPO, another azurophil granule-stored enzyme,
was also regulated in patients with CF. In contrast to PR3
mRNA, MPO mRNA could be detected both in neutrophils
and in monocytes and remained at the same level whether CF
patients were under stable condition or pulmonary exacerba-
tion (Fig. 2B and 3B).
4. Discussion
CF represents a model of neutrophil-dominated airway in-
£ammation and chronic bacterial colonization involving an
imbalance in the ratio of proteases to anti-proteases [4]. Since
PR3 is the only neutrophil serine protease not inhibited by
SLPI which is present at very high levels in sputum, we inves-
tigated the in vivo regulation of PR3 expression in both neu-
trophils and monocytes of CF patients.
In the present study, we ¢rst showed that circulating neu-
trophils contain much higher concentrations of PR3 than
monocytes. To our knowledge, such a comparative analysis
has not yet been reported. This important di¡erence (approx-
imately 20 times) could easily be explained by the well-docu-
mented observation of a much higher number of both azur-
ophil and secondary granules in mature neutrophils than in
monocytes [16]. A more important ¢nding was that the PR3
mRNA of monocytes could be signi¢cantly enhanced at the
time of CF pulmonary exacerbation. This was not the case
with neutrophils, although these cells have a protein synthesis
capacity, since recent studies have stressed their full capacity
to synthesize cytokines [17]. The potential signi¢cance of such
an upregulation of PR3 in monocytes both at the mRNA and
the protein level should be considered along the two following
aspects.
4.1. Fundamental implications of inducibility of PR3 expression
in circulating monocytes
PR3, together with other phagocytic cell granular enzymes
such as NE and MPO, is considered to be stored in intra-
cellular compartments and eventually released upon degranu-
lation. So far, neutrophils have been considered as the major
source of these granular enzymes and there was no evidence,
in these cells, of de novo biosynthesis and modulation of PR3
during in£ammatory/infectious processes. The expression and
Fig. 2. PR3 in neutrophils. (A) A representative May Grunwald
Giemsa stain of cytocentrifuged puri¢ed neutrophils. (B) Southern
blot analysis of RT-PCR products from neutrophils of three exem-
pli¢ed CF patients. 1, 3, 5 and 2, 4, 6 are three individual CF pa-
tients before (3) and after (+) antibiotic treatment, respectively.
MPO and L-actin were used as another phagocytic cell granular en-
zyme and an assessment of cDNA concentrations in each lane, re-
spectively.
Fig. 3. PR3 in monocytes. (A) A representative May Grunwald
Giemsa stain of cytocentrifuged puri¢ed monocytes. (B) Southern
blot analysis of RT-PCR products from monocytes. (C) Immuno-
blot analysis with anti-peptide PR3 antibody. In B and C, 1, 3, 5, 7
and 2, 4, 6, 8 are four individual CF patients before (3) and after
(+) antibiotic treatment, respectively.
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regulation of PR3 in monocytes clearly modi¢es this classical
picture. Our observation that PR3 can be upregulated in vivo
during the CF in£ammatory process may suggest a potential
regulatory role for PR3 in monocyte activation and especially
in cytokine processing, as previously described [10,11]. Thus,
besides its direct deleterious e¡ect on connective tissues largely
mediated by neutrophils, PR3 could be a mediator of in£am-
mation through its expression and regulation in monocytes
[18].
4.2. Clinical relevance of PR3 inducibility in CF
pathophysiology
The release of serine proteinases plays a role in the degra-
dation of the lung in patients with CF [19,20]. Our present
results suggest that the high concentrations of PR3 measured
in sputum [13] could be the result of both the neutrophils and
monocytes-derived alveolar macrophage producing PR3.
While numerous studies have shown the deleterious role of
neutrophils on lung tissues at very early stages of the disease
[21], the role of the monocytes has rarely been investigated.
However, monocytes were consistently found in blood vessels
and the adjacent interstitial space in areas with overt evidence
of ongoing in£ammation in patients with CF [22].
We have now shown that PR3 mRNA expression in periph-
eral blood cells of patients with pulmonary exacerbation is
restricted to monocytes, suggesting that the PR3 gene is newly
expressed during the in£ammatory process. The fact that in
contrast to PR3, MPO was not upregulated renders the spe-
ci¢c role of PR3 in the CF lung in£ammatory process more
accurate.
Although the ongoing in£ammation is restricted to the air-
ways, previous studies have shown that circulating neutrophils
are in a priming state in the very early phase of the disease
[23,24]. Likewise, we have now shown that circulating mono-
cytes may play a signi¢cant role in the in£ammatory process
since PR3 mRNA in these cells was highly correlated with the
in£ammatory status of the patient. Our present ¢ndings
stressed out that the PR3 content in circulating monocytes
is clearly a¡ected by, and could serve as a peripheral marker
of, pulmonary exacerbation and ongoing airway infection in
patients with CF.
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